<html><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta http-equiv="Content-Style-Type" content="text/css" /><meta name="generator" content="Aspose.Words for .NET 13.4.0.0" /><title>Written evidence submitted by Celgene Corporation (RAD005)</title></head><body><div><p style="margin:0pt"><span style="font-family:Cambria; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:center"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">Written evidence submitted by Celgene Corporation (RAD005)</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">1.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Celgene </span><span style="font-family:'Times New Roman'; font-size:11pt">is </span><span style="font-family:'Times New Roman'; font-size:11pt">delighted to respond to the Science and Technology Committee’s consultation on the funding available for R&amp;</span><span style="font-family:'Times New Roman'; font-size:11pt">D in science and technology in the UK. Although we are unable to respond to all aspects of the report produced by the National Audit Office into this issue, there are some specific comments in relation to R&amp;D in the life sciences sector that we would like </span><span style="font-family:'Times New Roman'; font-size:11pt">to be taken into consideration as the Committee progresses its investigation. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">1.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">By way of background, Celgene is a global biopharmaceutical company committed to improving the lives of patients worldwide. As a company, we seek to deliver truly innovative an</span><span style="font-family:'Times New Roman'; font-size:11pt">d life-changing medicines for our patients. In the UK we have developed a number of products for the treatment of cancer and other severe, immune, inflammatory conditions. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">1.3. There are four key issues discussed in this consultation response. These are:</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="display:inline; font-family:Wingdings; font-size:10pt; font-style:normal; font-weight:normal; text-decoration:none; text-transform:none; vertical-align:baseline"></span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The competitiveness of R&amp;D in the UK</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="display:inline; font-family:Wingdings; font-size:10pt; font-style:normal; font-weight:normal; text-decoration:none; text-transform:none; vertical-align:baseline"></span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The uptake of new medicines on the NHS</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="display:inline; font-family:Wingdings; font-size:10pt; font-style:normal; font-weight:normal; text-decoration:none; text-transform:none; vertical-align:baseline"></span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The role of Academic Health Science Networks (AHSNs)</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-align:justify; text-indent:-18pt"><span style="display:inline; font-family:Wingdings; font-size:10pt; font-style:normal; font-weight:normal; text-decoration:none; text-transform:none; vertical-align:baseline"></span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The potential of the Medicines and Healthcare Products Regulatory Agency’s (MHRA) Early Access Scheme</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">2. The competitiveness </span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">of R&amp;D in the UK</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Celgene believes that the UK should aim to be a market leader in R&amp;</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">D across the full life-cycle required for developing a new medicine. This means increasing focus on post approval safety studies, as well as on the initial recruitment of patients to a new study and translational research. It may be that some incentivisati</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">on is needed in this area. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Celgene would welcome greater consistency around the approval process and costs of conducting R&amp;D in the UK. The current discrepancy in the funding and data acquired to start a trial is creating too much uncertainty for companie</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">s in the UK. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">We would also support moves to enable organisations to recoup the non-refundable set up costs where clinical sites are unable to recruit sufficient patient numbers. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; orphans:0; text-align:justify; text-indent:-21.3pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">2.1 Pharmaceutical R&amp;D is an expensive business. A recent report by the UK </span><span style="font-family:'Times New Roman'; font-size:11pt">Office of Health Economics (OHE) suggests that the mean or average cost of researching and developing a successful new medicine has significantly increased over the last decade and is now estimated at US$1,506million, at 2011 prices.</span><a name="_ftnref1"></a><a href="#_ftn1">[1]</a><span style="font-family:'Times New Roman'; font-size:11pt"> According to the OHE, however, R&amp;D costs vary substantially by therapeutic area. The most recent analyses suggest that the most expensive therapeutic areas in terms of drug R&amp;D costs are neurology, respiratory and oncology.</span><a name="_ftnref2"></a><a href="#_ftn2">[2]</a><span style="font-family:'Times New Roman'; font-size:11pt"> This is because drugs in these categories experience lower success rates and longer development times.</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">They also represent some of the areas of greatest unmet need in medicine. This issue is exacerbated in the case of oncology by the UK’s ageing population, the associated increase in cancer incidence rates and by the poor outcomes in the UK relative to other EU countries. Research in these fields </span><span style="font-family:'Times New Roman'; font-size:11pt">is therefore of critical importance for the health and wellbeing of patients across the UK.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; orphans:0; text-align:justify; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; orphans:0; text-align:justify; text-indent:-21.3pt; widows:0"><span style="font-family:'Times New Roman'; font-size:11pt">2.2 </span><span style="font-family:'Times New Roman'; font-size:11pt">The pharmaceutical industry in the UK currently employs around 67,000 people directly – 25,000 of those in research and development. As the NAO outlined in their report, the majority of</span><span style="font-family:'Times New Roman'; font-size:11pt"> current research programmes in the UK are funded and carried out by the industry.</span><a name="_ftnref3"></a><a href="#_ftn3">[3]</a></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.3  Celgene is wholly supportive of the significant</span><span style="font-family:'Times New Roman'; font-size:11pt"> contribution the National Institute of Health Research’s (NIHR) biomedical research centres and units have made to the current environment for R&amp;D.  The new Coordinated System for gaining NHS Permission (CSP) has been effective in supporting high quality </span><span style="font-family:'Times New Roman'; font-size:11pt">clinical research studies in England. Celgene recognises the challenges of meeting the 30 day target for gaining permission for a new research project in partnership with the NIHR, </span><span style="font-family:'Times New Roman'; font-size:11pt">particularly given the length of contract discussions which must be conclud</span><span style="font-family:'Times New Roman'; font-size:11pt">ed before the trial can start, </span><span style="font-family:'Times New Roman'; font-size:11pt">but believes </span><span style="font-family:'Times New Roman'; font-size:11pt">a timely </span><span style="font-family:'Times New Roman'; font-size:11pt">review</span><span style="font-family:'Times New Roman'; font-size:11pt"> process</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">is an important factor in maintaining a competitive environment for R&amp;D.</span><span style="font-family:'Times New Roman'; font-size:11pt"> In many EU countries the process is more streamlined and efficient, as those conducting research do not need to secure R&amp;D approval, as well as approval from the European Commission and the MHRA</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.4  Celgene has a number of UK clinical trials which have </span><span style="font-family:'Times New Roman'; font-size:11pt">benefited from the support of the NIHR to recruit patients. In the majority of cases, their proactive approach to ensuring recruitment targets are met has been highly effective. </span><span style="font-family:'Times New Roman'; font-size:11pt">At</span><span style="font-family:'Times New Roman'; font-size:11pt"> one of </span><span style="font-family:'Times New Roman'; font-size:11pt">the</span><span style="font-family:'Times New Roman'; font-size:11pt"> sites</span><span style="font-family:'Times New Roman'; font-size:11pt"> Celgene works with</span><span style="font-family:'Times New Roman'; font-size:11pt">, </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt">Chief Investigator has worked clos</span><span style="font-family:'Times New Roman'; font-size:11pt">ely with NIHR nurses to ensure a sufficient number of patients are involved in the trial. The</span><span style="font-family:'Times New Roman'; font-size:11pt">ir contribution to </span><span style="font-family:'Times New Roman'; font-size:11pt">securing </span><span style="font-family:'Times New Roman'; font-size:11pt">patient consent </span><span style="font-family:'Times New Roman'; font-size:11pt">has been </span><span style="font-family:'Times New Roman'; font-size:11pt">vital in ensuring</span><span style="font-family:'Times New Roman'; font-size:11pt"> sufficient</span><span style="font-family:'Times New Roman'; font-size:11pt"> recruitment in</span><span style="font-family:'Times New Roman'; font-size:11pt">to the trial </span><span style="font-family:'Times New Roman'; font-size:11pt">which</span><span style="font-family:'Times New Roman'; font-size:11pt"> may not have otherwise </span><span style="font-family:'Times New Roman'; font-size:11pt">been achieved. The </span><span style="font-family:'Times New Roman'; font-size:11pt">learni</span><span style="font-family:'Times New Roman'; font-size:11pt">ngs from</span><span style="font-family:'Times New Roman'; font-size:11pt"> examples like</span><span style="font-family:'Times New Roman'; font-size:11pt"> this </span><span style="font-family:'Times New Roman'; font-size:11pt">are critical to feed</span><span style="font-family:'Times New Roman'; font-size:11pt">back into the system</span><span style="font-family:'Times New Roman'; font-size:11pt"> and a more consistent mechanism needs to be put in place to allow all those involved in clinical research to share their experiences – both positive and negative.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.5  Despite the vital </span><span style="font-family:'Times New Roman'; font-size:11pt">work of the NIHR, the system for approval for new clinical trials in the UK remains highly complex. Currently, approval must be gained from </span><span style="font-family:'Times New Roman'; font-size:11pt">each </span><span style="font-family:'Times New Roman'; font-size:11pt">site where the research is to be undertaken and each local R&amp;D office needs to be informed. There is no standar</span><span style="font-family:'Times New Roman'; font-size:11pt">d form between sites and the requirements vary for each. </span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.6</span><span style="font-family:'Times New Roman'; font-size:11pt">              </span><span style="font-family:'Times New Roman'; font-size:11pt">For a multi-site research project, this can be challenging and burdensome</span><span style="font-family:'Times New Roman'; font-size:11pt">, often slowing down the trial set up as a result. Other countries including </span><span style="font-family:'Times New Roman'; font-size:11pt">France, Germany, Italy, Canada, Spain, </span><span style="font-family:'Times New Roman'; font-size:11pt">Russia, Ukraine, Bulgaria and Romania all have less burdensome processes for gaining approval for new clinical studies</span><span style="font-family:'Times New Roman'; font-size:11pt"> and a standardi</span><span style="font-family:'Times New Roman'; font-size:11pt">s</span><span style="font-family:'Times New Roman'; font-size:11pt">ed process is therefore needed in the UK to make it more competitive on the global stage. </span><span style="font-family:'Times New Roman'; font-size:11pt"> </span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.7</span><span style="font-family:'Times New Roman'; font-size:11pt">  Celgene has real concer</span><span style="font-family:'Times New Roman'; font-size:11pt">ns that the cost of conducting clinical trials in the UK is prohibitive for many organisations</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span><span style="font-family:'Times New Roman'; font-size:11pt"> The fees charged by R&amp;D departments are not currently standardised and vary considerably</span><span style="font-family:'Times New Roman'; font-size:11pt">. In one of the studies Celgene has been involved in the per patient cos</span><span style="font-family:'Times New Roman'; font-size:11pt">t varied from £5,500.00 per patient to £9,900.00 per patient</span><span style="font-family:'Times New Roman'; font-size:11pt">. Despite the national costing template created by NIHR, this can make it difficult to plan for the costs of a major clinical trial programme and </span><span style="font-family:'Times New Roman'; font-size:11pt">some centres are so costly it is impossible for a </span><span style="font-family:'Times New Roman'; font-size:11pt">company like Celgene, which is a relatively new entrant to the UK market, to justify the expense</span><span style="font-family:'Times New Roman'; font-size:11pt"> when other countries across Europe and beyond </span><span style="font-family:'Times New Roman'; font-size:11pt">can be significantly cheaper than sites </span><span style="font-family:'Times New Roman'; font-size:11pt">in</span><span style="font-family:'Times New Roman'; font-size:11pt"> the UK.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.</span><span style="font-family:'Times New Roman'; font-size:11pt">8</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">Additionally</span><span style="font-family:'Times New Roman'; font-size:11pt">, set up costs - </span><span style="font-family:'Times New Roman'; font-size:11pt">which are non-refundable </span><span style="font-family:'Times New Roman'; font-size:11pt">- </span><span style="font-family:'Times New Roman'; font-size:11pt">can run into thousands of pounds. Whilst this is not an issue if the site delivers its quota of patients, this does </span><span style="font-family:'Times New Roman'; font-size:11pt">represent</span><span style="font-family:'Times New Roman'; font-size:11pt"> an increasing cost burden when they don’t. Celgene believes that R&amp;D fees should be standardised between sites in the UK and must </span><span style="font-family:'Times New Roman'; font-size:11pt">be made more transparent. The fees should be proportionate to the size and complexity of research projects and there should be a mechanism in place to recoup charges paid if a site fails to deliver the required quota of patients.</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic"> </span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 21.3pt; text-align:justify; text-indent:-21.3pt"><span style="font-family:'Times New Roman'; font-size:11pt">2.9</span><span style="font-family:'Times New Roman'; font-size:11pt">  The UK is currently focused on becoming a world leader in translational research and stratified medicines. Various partnerships and programmes have been set up to incentivise this work. </span><span style="font-family:'Times New Roman'; font-size:11pt">T</span><span style="font-family:'Times New Roman'; font-size:11pt">his is clearly an important and exciting area of research, which ha</span><span style="font-family:'Times New Roman'; font-size:11pt">s the potential to c</span><span style="font-family:'Times New Roman'; font-size:11pt">onfer huge benefits to patients. However,</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">it</span><span style="font-family:'Times New Roman'; font-size:11pt"> should not be pursued to the detriment of post-approval safety studies</span><span style="font-family:'Times New Roman'; font-size:11pt"> which are carried out at the </span><span style="font-family:'Times New Roman'; font-size:11pt">req</span><span style="font-family:'Times New Roman'; font-size:11pt">uest of approving authorities and are often a</span><span style="font-family:'Times New Roman'; font-size:11pt"> condition of approval</span><span style="font-family:'Times New Roman'; font-size:11pt">. It is vital that th</span><span style="font-family:'Times New Roman'; font-size:11pt">e research community continues to understand how new treatments work in real world settings and are able to understand the impact a treatment has on patients once it has gained approval. </span><span style="font-family:'Times New Roman'; font-size:11pt">We therefore welcome the development of the Systemic </span><span style="font-family:'Times New Roman'; font-size:11pt">Anti-Cancer Ther</span><span style="font-family:'Times New Roman'; font-size:11pt">apy </span><span style="font-family:'Times New Roman'; font-size:11pt">(SACT) data</span><span style="font-family:'Times New Roman'; font-size:11pt">base </span><span style="font-family:'Times New Roman'; font-size:11pt">which will provide important information about the</span><span style="font-family:'Times New Roman'; font-size:11pt"> clinical management in cancer chemotherapy</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">would encourage Government </span><span style="font-family:'Times New Roman'; font-size:11pt">to speed up other da</span><span style="font-family:'Times New Roman'; font-size:11pt">ta sets becoming mandatory so they</span><span style="font-family:'Times New Roman'; font-size:11pt"> can really add value quicker to the countries knowledge and insights</span><span style="font-family:'Times New Roman'; font-size:11pt">. </span><span style="font-family:'Times New Roman'; font-size:11pt">In line with the Government’s intention to measure the overall ‘value’ of a medicine, this kind of </span><span style="font-family:'Times New Roman'; font-size:11pt">information</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">can support us to understand the patient benefits of a new medicine and th</span><span style="font-family:'Times New Roman'; font-size:11pt">e impact it has on their quality of life. </span><span style="font-family:'Times New Roman'; font-size:11pt">It can also </span><span style="font-family:'Times New Roman'; font-size:11pt">help industry to make its case for funding for a new medicine, provide collateral to clinicians wishing to prescribe a new treatment and allow patients to understand the full benefits of the medicine th</span><span style="font-family:'Times New Roman'; font-size:11pt">ey are taking.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">3. Uptake of new medicines on the NHS needs to be incentivised</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Celgene would welcome greater clarity from the Department of Health on the speed and extent of take-up of new medicines once they have received approval. In particular, it is v</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">ital that,</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">once a new medicine is included in a local formulary</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> or nationally commissioned</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">, clinicians are encouraged to prescribe this treatment to patients where appropriate.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">3.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Once a medicine has been approved for use in the UK, companies continue to </span><span style="font-family:'Times New Roman'; font-size:11pt">struggle to have these placed on local formularies</span><span style="font-family:'Times New Roman'; font-size:11pt"> or built into national guidelines and pathways. As a result of this,</span><span style="font-family:'Times New Roman'; font-size:11pt"> patients report delays in their ability to access the new medicines they need.</span><span style="font-family:'Times New Roman'; font-size:11pt"> This is often caused by long delays in the NICE appraisal</span><span style="font-family:'Times New Roman'; font-size:11pt"> process </span><span style="font-family:'Times New Roman'; font-size:11pt">and </span><span style="font-family:'Times New Roman'; font-size:11pt">it is important that </span><span style="font-family:'Times New Roman'; font-size:11pt">barriers to prescribing </span><span style="font-family:'Times New Roman'; font-size:11pt">are not</span><span style="font-family:'Times New Roman'; font-size:11pt"> put in the way whilst decisions </span><span style="font-family:'Times New Roman'; font-size:11pt">by NICE </span><span style="font-family:'Times New Roman'; font-size:11pt">are </span><span style="font-family:'Times New Roman'; font-size:11pt">being </span><span style="font-family:'Times New Roman'; font-size:11pt">made</span><span style="font-family:'Times New Roman'; font-size:11pt">. To improve patients access it is vital that the NHS embrace</span><span style="font-family:'Times New Roman'; font-size:11pt"> new technology whilst it awaits a </span><span style="font-family:'Times New Roman'; font-size:11pt">formal appraisal </span><span style="font-family:'Times New Roman'; font-size:11pt">decision or </span><span style="font-family:'Times New Roman'; font-size:11pt">that NICE s</span><span style="font-family:'Times New Roman'; font-size:11pt">peed up their appraisal process </span><span style="font-family:'Times New Roman'; font-size:11pt">so patients don’t face </span><span style="font-family:'Times New Roman'; font-size:11pt">these </span><span style="font-family:'Times New Roman'; font-size:11pt">delays</span><span style="font-family:'Times New Roman'; font-size:11pt">. The introduction of value-based pricing (V</span><span style="font-family:'Times New Roman'; font-size:11pt">BP</span><span style="font-family:'Times New Roman'; font-size:11pt">)</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">should also not be allowed to cause</span><span style="font-family:'Times New Roman'; font-size:11pt"> greater delays</span><span style="font-family:'Times New Roman'; font-size:11pt"> in the appraisal process</span><span style="font-family:'Times New Roman'; font-size:11pt">.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">3.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Although positive steps have been made to overcome this challen</span><span style="font-family:'Times New Roman'; font-size:11pt">ge, including the introduction of the NICE Compliance Regime, progress remains slow. The Government must do more to ensure that the new structures across the NHS incentivise speedier access to medicines. The current status quo is both bad for patients – wh</span><span style="font-family:'Times New Roman'; font-size:11pt">o are forced to wait to receive new treatments – and bad for the life sciences industry, which invests heavily in the development of new medicines that do not get the take-up anticipated, despite support from clinicians and patients.</span><span style="font-family:'Times New Roman'; font-size:11pt"> It is also important t</span><span style="font-family:'Times New Roman'; font-size:11pt">o minimise the current </span><span style="font-family:'Times New Roman'; font-size:11pt">variation in uptake and </span><span style="font-family:'Times New Roman'; font-size:11pt">NHS E</span><span style="font-family:'Times New Roman'; font-size:11pt">ngland </span><span style="font-family:'Times New Roman'; font-size:11pt">must </span><span style="font-family:'Times New Roman'; font-size:11pt">look at best practice </span><span style="font-family:'Times New Roman'; font-size:11pt">across the country in order to</span><span style="font-family:'Times New Roman'; font-size:11pt"> ensure variation is minimized to best standards to ensure equality across UK.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">4. The role of Academic Health Science Networks (AHSNs)</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Celgene believes the Government should do more to incentivise industry involvement in AHSNs and would welcome AHSNs playing a more active role in creating simpler, more consistent approval processes for new clinical trials</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There is a huge amount of </span><span style="font-family:'Times New Roman'; font-size:11pt">overlap between the work of industry and the academic research community</span><span style="font-family:'Times New Roman'; font-size:11pt">. U</span><span style="font-family:'Times New Roman'; font-size:11pt">ltimately</span><span style="font-family:'Times New Roman'; font-size:11pt">,</span><span style="font-family:'Times New Roman'; font-size:11pt"> both are looking to achieve the same outcomes – access to the best, new treatments for patients in the UK at the appropriate point in the patient journey.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Good science a</span><span style="font-family:'Times New Roman'; font-size:11pt">nd good investment is equally important to both parties. It is easier to harness funding and access the best data when organisations from industry and academia work together. More needs to be done to promote and incentivise partnership working where this w</span><span style="font-family:'Times New Roman'; font-size:11pt">ill lead to improvements for patients. AHSNs are a welcome step in the right direction. However, their interaction with industry has been mixed – whilst some see collaboration with industry as core to what they do, others have failed to engage at all. It w</span><span style="font-family:'Times New Roman'; font-size:11pt">ould be useful for the Department of Health and the Department of Business, Innovation and Skills to indicate that collaboration through these networks is important to their success and share examples of best practice in cross-sector partnerships.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:normal">4.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">An impo</span><span style="font-family:'Times New Roman'; font-size:11pt">rtant change that could be achieved fairly easily would be to create super-networks in which three or four AHSNs come together to create a single </span><span style="font-family:'Times New Roman'; font-size:11pt">R&amp;D/ i</span><span style="font-family:'Times New Roman'; font-size:11pt">nstitutional </span><span style="font-family:'Times New Roman'; font-size:11pt">approval process for new clinical trials. This would simplify and streamline the process in</span><span style="font-family:'Times New Roman'; font-size:11pt">volved in setting up new R&amp;D projects and provide a greater pool of patients to recruit to the trials. This cross-AHSN collaboration is already taking place in some parts of the country and more should be done to make the individual networks accountable fo</span><span style="font-family:'Times New Roman'; font-size:11pt">r ensuring the competitiveness of the UK as an environment for R&amp;D.</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">5. The potential of the MHRA’s Early Access Scheme</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 10pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">Celgene urges the Government to provide greater clarity on the direction of travel of the MHRA’s Early Access Scheme.</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">We also advocate</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold"> that the MHRA looks closely at areas where initiatives similar to the Early Access Scheme have been implemented. In particular, learnings should be taken from the ATU de cohort and the Centre for Accelerating Medical Innovations to inform and shape the Ea</span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">rly Access Scheme in the UK.</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.1</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">Celgene </span><span style="font-family:'Times New Roman'; font-size:11pt">in principle </span><span style="font-family:'Times New Roman'; font-size:11pt">supports the MHRA’s proposed early access scheme, which will help ensure that patients can have access to medicines earlier in the product lifecycle, including – assuming that adequate safety data is availa</span><span style="font-family:'Times New Roman'; font-size:11pt">ble – during the late development and regulatory phases, prior to marketing authorisation. This is particularly important for products that have the potential to deliver particular benefits to patients – either because they are to be licensed for particula</span><span style="font-family:'Times New Roman'; font-size:11pt">rly rare conditions, such as rarer forms of cancer, or for conditions where there is high unmet medical need or few alternative treatment options for patients. </span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.2</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">This scheme can, in particular, support the </span><span style="font-family:'Times New Roman'; font-size:11pt">all those involved in clinical research</span><span style="font-family:'Times New Roman'; font-size:11pt"> </span><span style="font-family:'Times New Roman'; font-size:11pt">(and those</span><span style="font-family:'Times New Roman'; font-size:11pt"> that are potential beneficiaries of the clinical research) </span><span style="font-family:'Times New Roman'; font-size:11pt">to collect high quality real life data which can provide significant insight into the effectiveness of a new medicine. It will support more widespread use of innovative new treatments that can del</span><span style="font-family:'Times New Roman'; font-size:11pt">iver positive outcomes for patients for whom there are currently very few treatment opportunities available. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:130%; margin:0pt 0pt 0pt 18pt; text-align:justify; text-indent:-18pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.3</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">However, greater clarity is urgently needed as to how this scheme will work in practice – in particular, what will the process be for selecting s</span><span style="font-family:'Times New Roman'; font-size:11pt">uitable products and reviewing the available data; how will the MHRA engage other stakeholders (including industry and patients) in the process; and what monitoring and evaluation mechanisms will be put in place to ensure that the scheme meets its desired </span><span style="font-family:'Times New Roman'; font-size:11pt">objective of improving early access to new medicines? </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.4</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The MHRA should look at other schemes that are in place or in development abroad to improve the early access scheme proposed in the UK. As you may be aware, a</span><span style="font-family:'Times New Roman'; font-size:11pt; font-weight:bold"> </span><span style="font-family:'Times New Roman'; font-size:11pt">number of EU Member States have put in place national arrangements similar to the early access scheme with the intention to increase availability to promising new products for a cohort of patients where there is unmet need. The most well-known of these is </span><span style="font-family:'Times New Roman'; font-size:11pt">the </span><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">Autorisations Temporaires d’Utilisation de cohorte </span><span style="font-family:'Times New Roman'; font-size:11pt">(ATU de cohorte), which was introduced in France in 1994 and where more than 130 medicines were granted an ATU de cohorte in therapeutic areas, including oncology-haematology, CNS, infectious diseases and metabolism (including rare diseases). Feedback sugg</span><span style="font-family:'Times New Roman'; font-size:11pt">ests that the positive impact of this national scheme has been attributable to the fact that these products are subject to reimbursement. Although this has not been an unbridled success, it does provide an opportunity for the MHRA to learn the lessons from</span><span style="font-family:'Times New Roman'; font-size:11pt"> elsewhere as they design their own scheme. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.5</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">The development of innovative medicines is a highly regulated, lengthy and expensive undertaking and the continued research and development of novel products to treat areas of unmet medical need should be incen</span><span style="font-family:'Times New Roman'; font-size:11pt">tivised by appropriate reimbursement policies. If a similar scheme </span><span style="font-family:'Times New Roman'; font-size:11pt">to the ATU de cohort </span><span style="font-family:'Times New Roman'; font-size:11pt">were to be introduced in the UK, an appropriate level of reimbursement should be considered to incentivise innovation by the research community and companies.</span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt 0pt 0pt 17.85pt; text-align:justify; text-indent:-17.85pt"><span style="font-family:'Times New Roman'; font-size:11pt">5.6</span><span style="font:7.0pt 'Times New Roman'">&#xa0;&#xa0; </span><span style="font-family:'Times New Roman'; font-size:11pt">There is</span><span style="font-family:'Times New Roman'; font-size:11pt"> also much to be supported in the proposals for adaptive licensing, being developed by the Centre for Accelerating Medical Innovations at Oxford University. Over the past five years a number of schemes have been put forward that take a more adaptive approa</span><span style="font-family:'Times New Roman'; font-size:11pt">ch to market access</span><span style="font-family:'Times New Roman'; font-size:11pt">, such as</span><span style="font-family:'Times New Roman'; font-size:11pt"> ‘staggered approval’, ‘conditional licensing’ and ‘progressive approval’. The central elements of all these new systems and the important factor that should be incorporated into the early access scheme is not the design but the</span><span style="font-family:'Times New Roman'; font-size:11pt"> collaboration between academia, manufacturers, </span><span style="font-family:'Times New Roman'; font-size:11pt">healthcare professionals, the regulators, patient groups and – increasingly – reimbursement agencies</span><a name="_GoBack"></a><span style="font-family:'Times New Roman'; font-size:11pt">. </span></p><p style="margin:0pt 0pt 0pt 36pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic; font-weight:bold">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt">&#xa0;</span></p><p style="font-size:11pt; line-height:120%; margin:0pt; text-align:justify"><span style="font-family:'Times New Roman'; font-size:11pt; font-style:italic">August 2013</span></p><p style="margin:0pt"><span style="font-family:Cambria; font-size:11pt">&#xa0;</span></p><p style="margin:0pt 18pt 0pt 0pt"><span style="font-family:Calibri; font-size:11pt">&#xa0;</span></p></div><hr style="width:33%; height:1px; text-align:left" /><p style="font-size:8pt; line-height:120%; margin:0pt"><a name="_ftn1"></a><a href="#_ftnref1">[1]</a><span style="font-family:Arial; font-size:8pt"> Mestre-Ferrandiz, J., Sussex, J. and Towse, A. The R &amp; D Cost of a New Medicine. Office of Health Economics. 2012. Executive Summary. p. v.</span></p><p style="font-size:8pt; line-height:120%; margin:0pt; orphans:0; widows:0"><a name="_ftn2"></a><a href="#_ftnref2">[2]</a><span style="font-family:Arial; font-size:8pt"> Mestre-Ferrandiz, J., Sussex, J. and Towse, A. Op.cit. p. vi.</span></p><p style="font-size:8pt; line-height:120%; margin:0pt"><a name="_ftn3"></a><a href="#_ftnref3">[3]</a><span style="font-family:Arial; font-size:8pt"> National Audit Office. Research and Development funding for science and technology in the UK, Memorandum for the House of Commons Science and Technology Committee, 2013. P.vii </span></p><p style="margin:0pt"><span style="font-family:Cambria; font-size:10pt">&#xa0;</span></p></body></html>